Bob Valamehr
鲍勃·瓦拉梅尔
PhD
Chief Development Officer首席开发官
👥Biography 个人简介
Pioneer in iPSC-derived cell therapy, leading development of FT596 and other off-the-shelf NK cell programs at Fate Therapeutics. His work on clonal iPSC master cell banks enables reproducible, scalable production of engineered NK and T cells.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
iPSC-Derived NK Cell Platform
Established the iPSC master cell bank platform enabling clonal derivation of uniformly engineered NK cells, advancing FT596 as the first multi-antigen-targeted iPSC-derived CAR-NK cell into clinical trials.
Representative Works 代表性著作
Prospective Generation of Clone-and Antigen-Specific NK Cells from Human Pluripotent Stem Cells
Stem Cell Reports (2021)
Demonstrated iPSC-to-NK differentiation with functional anti-tumor activity, supporting off-the-shelf iPSC-NK cell therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Carl H. June
University of Pennsylvania
Michel Sadelain
Memorial Sloan Kettering Cancer Center
Crystal L. Mackall
Stanford University
Katy Rezvani
MD Anderson Cancer Center
关注 鲍勃·瓦拉梅尔 的研究动态
Follow Bob Valamehr's research updates
留下邮箱，当我们发布与 Bob Valamehr（Fate Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment